Dali Pharmaceuticalco.,Ltd (603963.SS)
CNY 2.96
(-3.27%)
CNY 2.96
(-3.27%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -26 Million | -3.72 Million | 10.5 Million | -6.35 Million | 7.32 Million | 78.11 Million |
| Net Income | -20.03 Million | -17.7 Million | -41.89 Million | 3.23 Million | 13.5 Million | 10.7 Million |
| Depreciation & Amortization | 2.38 Million | 17.84 Million | 17.5 Million | 15.93 Million | 16.34 Million | 18.14 Million |
| Deferred income taxes | 2.32 Million | 703.96 Thousand | -360.94 Thousand | 544.24 Thousand | 4.45 Million | -5.11 Million |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -16.81 Million | 1.16 Million | 7.32 Million | -18.9 Million | -16.4 Million | 53.55 Million |
| Other non-cash items | 1.7 Million | -5.04 Million | 27.57 Million | -6.61 Million | -6.11 Million | -4.28 Million |
| Investing Cash Flow | 20.36 Million | -120.35 Million | 90.66 Million | -32.35 Million | -15.33 Million | 13.4 Million |
| Investments in PPE | -7.69 Million | -29.47 Million | -24.19 Million | -23.8 Million | -21.86 Million | -3.61 Million |
| Acquisitions | 132.8 Thousand | 0.49 | 200.00 | 23.93 Million | 21.86 Million | - |
| Investment purchases | -340 Million | -364 Million | -372 Million | -240 Million | -225 Million | -225 Million |
| Sales/Maturities of investments | 367.92 Million | 273.11 Million | 486.86 Million | 231.33 Million | 231.53 Million | 242.01 Million |
| Other Investing Activities | 28.06 Million | - | 0.01 | -23.8 Million | -21.86 Million | -0.34 |
| Financing Cash Flow | -24 Million | -12.73 Million | 16.14 Million | 19.4 Million | -10.01 Million | -60.62 Million |
| Debt repayment | -19.74 Million | -23.25 Million | -10 Million | -20 Million | - | -50 Million |
| Dividends payments | -1.63 Million | -2.2 Million | -10.1 Million | -594.05 Thousand | -10.01 Million | -10.62 Million |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | -2.61 Million | 12.72 Million | 37.74 Million | 39.99 Million | - | -50 Million |
| Accounts receivables | 4.14 Million | 1.4 Million | 2.63 Million | 6.25 Million | 10.73 Million | -19.29 Million |
| Accounts payables | 9.93 Million | 452.8 Thousand | -10.36 Million | -14.67 Million | -39.48 Million | 30.87 Million |
| Inventory | -33.22 Million | -1.39 Million | 15.41 Million | -11.02 Million | 7.89 Million | 47.08 Million |
| Other working capital | 12.26 Million | 703.96 Thousand | -360.94 Thousand | 544.24 Thousand | 4.45 Million | 6.47 Million |
| Cash at beginning of period | 43.83 Million | 180.65 Million | 63.33 Million | 82.63 Million | 100.64 Million | 69.75 Million |
| Cash at end of period | 14.19 Million | 43.83 Million | 180.65 Million | 63.33 Million | 82.63 Million | 100.64 Million |
| Capital Expenditure | -7.69 Million | -29.47 Million | -24.19 Million | -23.8 Million | -21.86 Million | -3.61 Million |
| Effect of forex changes on cash | - | -0.49 | 1.00 | 0.45 | 0.91 | 0.34 |
| Net cash flow / Change in cash | -29.64 Million | -136.81 Million | 117.32 Million | -19.3 Million | -18.01 Million | 30.89 Million |
| Free Cash Flow | -33.7 Million | -33.2 Million | -13.68 Million | -30.16 Million | -14.53 Million | 74.5 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -6.77 Million | -5.37 Million | -20.03 Million | -4.64 Million | -4.6 Million | -8.23 Million |
| Depreciation & Amortization | 2.16 Million | 2.16 Million | 2.38 Million | 17.82 Million | -9.79 Million | 4.45 Million |
| Deferred income taxes | - | - | 2.32 Million | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | 5.56 Million | - | -16.81 Million | -29.07 Million | 4.73 Million | -4.73 Million |
| Other non-cash items | 19.18 Million | 2.2 Million | 1.7 Million | 22.98 Million | -2.24 Million | -4.4 Million |
| Investing Cash Flow | 94.78 Million | 28.9 Million | 20.36 Million | -1.52 Million | -69.55 Million | 71.49 Million |
| Investments in PPE | -252.72 Thousand | -1.09 Million | -7.69 Million | -2.21 Million | -787.81 Thousand | -2.35 Million |
| Acquisitions | 40 Thousand | - | 132.8 Thousand | - | 0.22 | -73.85 Million |
| Investment purchases | - | -120 Million | -340 Million | -55 Million | -150 Million | -55 Million |
| Sales/Maturities of investments | 95 Million | 150 Million | 367.92 Million | 55.69 Million | 81.22 Million | 128.85 Million |
| Other Investing Activities | 96.03 Million | 32.1 Million | 28.06 Million | 693.19 Thousand | - | 73.85 Million |
| Financing Cash Flow | -5.29 Million | -252.69 Thousand | -24 Million | -7.94 Million | -348.38 Thousand | -12.72 Million |
| Debt repayment | -3.5 Million | - | -19.74 Million | -7.5 Million | -12.24 Million | - |
| Dividends payments | -246.99 Thousand | -252.69 Thousand | -1.63 Million | -332.53 Thousand | -348.38 Thousand | -470.96 Thousand |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | -246.99 Thousand | -252.69 Thousand | -2.61 Million | -111.35 Thousand | 12.24 Million | -12.24 Million |
| Accounts receivables | 1.96 Million | - | 4.14 Million | 4.14 Million | 4.59 Million | -4.59 Million |
| Accounts payables | - | - | 9.93 Million | - | - | - |
| Inventory | 3.59 Million | - | -33.22 Million | -33.22 Million | 139.74 Thousand | -139.74 Thousand |
| Other working capital | - | - | - | - | - | - |
| Cash at beginning of period | 39.68 Million | 16.56 Million | 43.83 Million | 16.56 Million | 99.61 Million | 55.59 Million |
| Cash at end of period | 139.4 Million | 39.68 Million | 14.19 Million | 14.19 Million | 16.56 Million | 99.61 Million |
| Capital Expenditure | -252.72 Thousand | -1.09 Million | -7.69 Million | -2.21 Million | -787.81 Thousand | -2.35 Million |
| Effect of forex changes on cash | - | - | - | - | -1.22 Million | -1.85 Million |
| Net cash flow / Change in cash | 99.72 Million | 23.11 Million | -29.64 Million | -2.37 Million | -83.04 Million | 44.01 Million |
| Free Cash Flow | 9.98 Million | -4.26 Million | -33.7 Million | 4.87 Million | -12.69 Million | -15.26 Million |
SHRICON
ORGN
002019
300486
DNA
EGS745W1C011